138 related articles for article (PubMed ID: 28373754)
21. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.
Møller MB; Pedersen NT; Christensen BE
Br J Haematol; 2004 Jan; 124(2):151-9. PubMed ID: 14687024
[TBL] [Abstract][Full Text] [Related]
22. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
[TBL] [Abstract][Full Text] [Related]
23. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
[TBL] [Abstract][Full Text] [Related]
24. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of survival and treatment outcome of young patients with high-risk diffuse large B cell lymphoma].
Yang P; Jing HM; Zhao W; Hu K; Dong F; Li QH; Wan W; Tian L; Wang JJ; Ke XY
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(32):2485-2490. PubMed ID: 28835053
[No Abstract] [Full Text] [Related]
26. Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.
Besson C; Lancar R; Prevot S; Algarte-Genin M; Delobel P; Bonnet F; Meyohas MC; Partisani M; Oberic L; Gabarre J; Goujard C; Boue F; Coppo P; Costello R; Hendel-Chavez H; Mekerri N; Dos Santos G; Recher C; Delarue R; Casasnovas RO; Taoufik Y; Mounier N; Costagliola D;
AIDS; 2017 Nov; 31(18):2493-2501. PubMed ID: 28926410
[TBL] [Abstract][Full Text] [Related]
27. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
28. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
29. Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type.
Lee WJ; Won KH; Won CH; Chang SE; Choi JH; Moon KC; Park CS; Huh J; Suh C; Lee MW
Acta Derm Venereol; 2016 Feb; 96(2):245-50. PubMed ID: 26014205
[TBL] [Abstract][Full Text] [Related]
30. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of survival and treatment outcome of patients with primary diffuse large B cell lymphoma in reproductive system].
Yang P; Zhen JF; Pang M; Hu K; Zhao W; Dong F; Tian L; Ke XY; Jing HM
Zhonghua Yi Xue Za Zhi; 2018 May; 98(20):1593-1596. PubMed ID: 29886651
[No Abstract] [Full Text] [Related]
32. A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry.
Gang AO; Pedersen M; d'Amore F; Pedersen LM; Jensen BA; Jensen P; Møller MB; Mourits-Andersen HT; Pedersen RS; Klausen TW; de N Brown P
Leuk Lymphoma; 2015; 56(9):2556-62. PubMed ID: 25629994
[TBL] [Abstract][Full Text] [Related]
33. [Clinical manifestation and treatment of extranodal diffuse large B-cell lymphoma].
Tomita N
Rinsho Ketsueki; 2016; 57(10):1991-1999. PubMed ID: 27725597
[TBL] [Abstract][Full Text] [Related]
34. The pretreatment albumin to globulin ratio as a significant predictor in patients with diffuse large B cell lymphoma.
Yue W; Liu B; Gao L; He M; Wang J; Zhang W; Chen L; Hu X; Xu L; Yang J
Clin Chim Acta; 2018 Oct; 485():316-322. PubMed ID: 30006285
[TBL] [Abstract][Full Text] [Related]
35. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
36. Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
Melén CM; Enblad G; Sonnevi K; Junlén HR; Smedby KE; Jerkeman M; Wahlin BE
Br J Haematol; 2016 Nov; 175(4):614-622. PubMed ID: 27790699
[TBL] [Abstract][Full Text] [Related]
37. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
38. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
39. [Expression of CD30 in Diffuse Large B Cell Lymphoma and Its Clinical Significance].
Zhao YF; Qian SX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):717-21. PubMed ID: 27342497
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]